Akira Yokoyama

Akira Yokoyama

Auto-generated profile, based on publicly available information

Akira Yokoyama

Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
HHHidenari Hirata
Hidenari Hirata
ANAtsushi Niida
Atsushi Niida
NKNobuyuki Kakiuchi
Nobuyuki Kakiuchi
RURyutaro Uchi
Ryutaro Uchi
KSKeishi Sugimachi
Keishi Sugimachi
KMKoshi Mimori
Koshi Mimori
Esophageal squamous cell carcinoma (ESCC) often recurs after chemoradiotherapy, and the prognosis of ESCC after chemoradiotherapy has not improved over the past few decades. The mutation process in chemoradiotherapy-resistant clones and the functional relevance of genetic alterations remain unclear. To address these problems, we performed whole-exome sequencing of 52 tumor samples from 33 patients with ESCC who received radiotherapy combined with 5-fluorouracil/platinum. In multiregion analyses of pretreatment and locally recurrent lesions from five cases, most driver gene-altered clones remained under chemoradiotherapy selection pressure, while few driver gene alterations were acquired at recurrence. The mutation signatures of recurrent ESCC, including increased deletion frequency and platinum dose-dependent base substitution signatures, were substantially different from those of primary ESCC and reflected the iatrogenic impacts of chemoradiotherapy. Single-region analysis of 28 pretreatment tumors indicated that focal copy-number gain at the MYC locus was significantly associated with poor progression-free survival and overall survival after chemoradiotherapy. MYC gain remained throughout the chemoradiotherapy course and potentially contributes to intrinsic resistance to chemoradiotherapy. Consistent with these findings, MYC copy number and mRNA and protein levels in ESCC cell lines correlated positively with resistance to radiotherapy, and MYC knockdown improved sensitivity to radiotherapy. Overall, these data characterize the clonal evolution process induced by chemoradiotherapy and clinically relevant associations for genetic alterations in ESCC. These findings increase our understanding of therapeutic resistance and support the rationale for precision chemoradiotherapy. Significance: Whole-exome sequencing reveals the genetic evolution of ESCC during chemoradiotherapy, highlighting MYC gain in pretreatment tumors as a potential marker of therapy resistance.

16 May 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
TKTomohiro Kadota
Tomohiro Kadota
SASeiirhicro Abe
Seiirhicro Abe
NUNoriya Uedo
Noriya Uedo
HDHisashi Doyama
Hisashi Doyama
YFYasuaki Furue
Yasuaki Furue
Tomonori YanoTomonori Yano
Tomonori Yano
INTRODUCTION: The early detection of gastric neoplasms (GNs) leads to favorable treatment outcomes. The latest endoscopic system, EVIS X1, includes third-generation narrow-band imaging (3G-NBI), texture and color enhancement imaging (TXI), and high-definition white-light imaging (WLI). Therefore, this randomized phase II trial aimed to identify the most promising imaging modality for GN detection using 3G-NBI and TXI. METHODS: Patients with scheduled surveillance endoscopy after a history of esophageal cancer or GN or preoperative endoscopy for known esophageal cancer or GN were randomly assigned to the 3G-NBI, TXI, or WLI groups. Endoscopic observations were performed to detect new GN lesions, and all suspected lesions were biopsied. The primary endpoint was the GN detection rate during primary observation. Secondary endpoints were the rate of missed GNs, early gastric cancer detection rate, and positive predictive value for a GN diagnosis. The decision rule had a higher GN detection rate between 3G-NBI and TXI, outperforming WLI by >1.0%. RESULTS: Finally, 901 patients were enrolled and assigned to the 3G-NBI, TXI, and WLI groups (300, 300, and 301 patients, respectively). GN detection rates in the 3G-NBI, TXI, and WLI groups were 7.3, 5.0, and 5.6%, respectively. The rates of missed GNs were 1.0, 0.7, and 1.0%, the detection rates of early gastric cancer were 5.7, 4.0, and 5.6%, and the positive predictive values for the diagnosis of GN were 36.5, 21.3, and 36.8% in the 3G-NBI, TXI, and WLI groups, respectively. DISCUSSION: Compared with TXI and WLI, 3G-NBI is a more promising modality for GN detection.

1 September 2003 in Metabolism
Verified
Journal Article
Closed access
CMChisato Murata
Chisato Murata
TWTetsu Watanabe
Tetsu Watanabe
HFHiroyuki Furuya
Hiroyuki Furuya
YSYoshihiko Sugioka
Yoshihiko Sugioka
HMHajime Mikurube
Hajime Mikurube
IOIsao Okazaki
Isao Okazaki

5 May 2013 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
SMSatoru Miura
Satoru Miura
SWSatoshi Watanabe
Satoshi Watanabe
KSKazuhiro Sato
Kazuhiro Sato
MMMasato Makino
Masato Makino
OKOsamu Kobayashi
Osamu Kobayashi
HYHirohisa Yoshizawa
Hirohisa Yoshizawa

1 January 1990 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
YFYasuhisa Fujibayashi
Yasuhisa Fujibayashi
KMKazuya Matsumoto
Kazuya Matsumoto
YAYasushi Arano
Yasushi Arano
YYYoshiharu Yonekura
Yoshiharu Yonekura
JKJunji Konishi
Junji Konishi
AYAkira Yokoyama
Akira Yokoyama
62Cu-Labeling of human serum albumin-dithiosemicarbazone (HSA-DTS) conjugate was performed using a newly developed 62Zn/62Cu generator system. HSA-DTS was easily labeled with 62Cu, by simple mixing with 62Cu-generator eluate. In vivo blood clearance of 62Cu-HSA-DTS was similar to 131I-HSA, indicating the high applicability of 62Cu-HSA-DTS as a method for plasma volume measurement. In a positron emission tomography study of a dog, a clear plasma pool image of the head region was obtained.

1 December 2001 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HSHiroshi Sakai
Hiroshi Sakai
SYShuichi Yoneda
Shuichi Yoneda
TTTomohide Tamura
Tomohide Tamura
YNYutaka Nishiwaki
Yutaka Nishiwaki
AYAkira Yokoyama
Akira Yokoyama
NSNagahiro Saijo
Nagahiro Saijo